Jason CPA - OnKure Therapeutics, Chief Officer
| OKUR Stock | 8.38 0.33 4.10% |
Executive
Jason CPA is Chief Officer of OnKure Therapeutics,
| Age | 50 |
| Address | 6707 Winchester Circle, Boulder, CO, United States, 80301 |
| Phone | 720 307 2892 |
| Web | https://onkuretherapeutics.com |
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| BBus FCPA | Telix Pharmaceuticals Limited | 59 | |
| MAcc CPA | Opus Genetics, | 43 | |
| Kyahn BA | Telix Pharmaceuticals Limited | N/A | |
| Ashwath Jayagopal | Opus Genetics, | 42 | |
| Angela Walsh | Dogwood Therapeutics, | 58 | |
| Joseph MBA | Opus Genetics, | 59 | |
| Bindu Manne | Opus Genetics, | N/A | |
| Ralph MPH | Dogwood Therapeutics, | 55 | |
| Lena LLB | Telix Pharmaceuticals Limited | N/A | |
| MBA MD | Telix Pharmaceuticals Limited | 55 | |
| Craig Ulrick | Telix Pharmaceuticals Limited | N/A | |
| Richard MBA | Telix Pharmaceuticals Limited | 49 | |
| Andreas MD | Telix Pharmaceuticals Limited | 59 | |
| Carol Duffy | Dogwood Therapeutics, | N/A | |
| Bernhard MBA | Opus Genetics, | 68 | |
| Nirav CFA | Opus Genetics, | 46 | |
| BSc BSc | Telix Pharmaceuticals Limited | N/A | |
| Darren Patti | Telix Pharmaceuticals Limited | 52 | |
OnKure Therapeutics, Leadership Team
Elected by the shareholders, the OnKure Therapeutics,'s board of directors comprises two types of representatives: OnKure Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OnKure. The board's role is to monitor OnKure Therapeutics,'s management team and ensure that shareholders' interests are well served. OnKure Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OnKure Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Litwiler, Senior Pharmacology | ||
| Jason CPA, Chief Officer | ||
| Pr Liu, Member Board | ||
| Rogan JD, General Secretary | ||
| Nicholas Saccomano, CEO President | ||
| Dylan Hartley, Chief Officer | ||
| Richard Woessner, Senior Pharmacology | ||
| James Blake, Senior Discovery | ||
| Rogan Nunn, General Secretary | ||
| Anthony Piscopio, President CoFounder | ||
| Duncan Walker, Chief Officer | ||
| Mark Boys, Senior Chemistry | ||
| MPH MD, Chief Officer |
OnKure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OnKure Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Net Income | (35.31 M) | ||||
| Total Debt | 137.58 M | ||||
| Total Asset | 35.73 M | ||||
| Retained Earnings | (102.05 M) | ||||
| Working Capital | 26.48 M | ||||
| Net Asset | 35.73 M |
Pair Trading with OnKure Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OnKure Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OnKure Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving against OnKure Stock
| 0.77 | EVLO | Evelo Biosciences | PairCorr |
| 0.71 | VAXX | Vaxxinity | PairCorr |
| 0.64 | FRTX | Fresh Tracks Therapeutics | PairCorr |
| 0.63 | FBIOP | Fortress Biotech Pref | PairCorr |
| 0.57 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to OnKure Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OnKure Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OnKure Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OnKure Therapeutics, to buy it.
The correlation of OnKure Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OnKure Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OnKure Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OnKure Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for OnKure Stock Analysis
When running OnKure Therapeutics,'s price analysis, check to measure OnKure Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OnKure Therapeutics, is operating at the current time. Most of OnKure Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of OnKure Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OnKure Therapeutics,'s price. Additionally, you may evaluate how the addition of OnKure Therapeutics, to your portfolios can decrease your overall portfolio volatility.